Switch to mania after ayahuasca consumption in a man with bipolar disorder: a case report

International Journal of Bipolar Disorders

Volumn 3, Issue 1, 2015, Pages

  Szmulewicz, Alejandro G ^a,b   Valerio, Marina P ^a   Smith, Jose M ^a  

^a Hospital Alvear   (Argentina)

^b FAVALORO UNIVERSITY   (Argentina)

Author keywords

Ayahuasca; Bipolar disorder; DSM 5; MAO inhibitors; Switch to mania

Indexed keywords

CLONAZEPAM; HARMINE; RISPERIDONE;

ACUTE PSYCHOSIS; ADULT; ANHEDONIA; APATHY; ARTICLE; AUDITORY HALLUCINATION; BIPOLAR I DISORDER; CASE REPORT; DEPRESSION; EUPHORIA; HOPELESSNESS; HUMAN; HYPOMANIA; LOGORRHEA; MALE; PARANOIA; PRIORITY JOURNAL; SLEEP DISORDER; THOUGHT DISORDER;

EID: 84952988271     PISSN: None     EISSN: 21947511     Source Type: Journal    
DOI: 10.1186/s40345-014-0020-y     Document Type: Article

References (17)

1. American Psychiatric Association. Diagnostic and statistical manual for mental disorders. 5th ed. Washington, DC: American Psychiatric Association; 2013.
2. Ben Salah N, Amamou M, Jerbi Z, Ben Salah F, Yacoub M. Aspects cliniques, pharmacologiques et toxicologiques du surdosage par une plante medicinale: le harmel. Essaydali Scientifique. 1986;21:13–8.
3. Callaway JC, Brito GS, Neves ES. Phytochemical analyses of Banisteriopsis caapi and Psychotria viridis. J Psychoactive Drugs. 2005;37(2):145–50.
4. Frison G, Favretto D, Zancanaro F, Fazzin G, Ferrara SD. A case of beta-carboline alkaloid intoxication following ingestion of Peganum harmala seed extract. Forensic Sci Int. 2008;179:e37–43.
5. Gable RS. Risk assessment of ritual use of oral dimethyltryptamine (DMT) and harmala alkaloids. Addiction. 2007;102(1):24–34.
6. Glennon RA, Dukat M, Grella B, Hong S, Costantino L, Teitler M, et al. Binding of b-carbolines and related agents at serotonin (5-HT2 and 5-HT1A), dopamine (D2) and benzodiazepine receptors. Drug Alcohol Depend. 2000;60(2):121–32.
7. Guimaraes dos Santos R. The pharmacology of ayahuasca: a review. Brasilia Med. 2010;47(2):188–95.
8. Herraiz T, Gonzalez D. beta-Carboline alkaloids in Peganum harmala and inhibition of human monoamine oxidase (MAO). Food Chem Toxicol. 2010;48(3):839–45.
9. Herraiz T, Gonzalez D, Ancin-Azpilicueta C, Aran VJ, Guillen H. beta-Carboline alkaloids in Peganum harmala and inhibition of human [MAO]. Food ChemToxicol. 2010;48(3):839–45.
10. Mahmoudian M, Jalilpour H, Salehian P. Toxicity of Peganum harmala: review and a case report. Iran J Pharmacol Ther. 2002;1:1–4.
11. McKenna DJ. Clinical investigations of the therapeutic potential of ayahuasca: rationale and regulatory challenges. Pharmacology& Therapeutics. 2004;102:111–29.
12. McKenna DJ, Callaway JC, Grob CS. The scientific investigation of ayahuasca: a review of past and current research. Heffter Rev Psychedelic Res. 1998;1:65–77.
13. Ng F, Berk M, Dean O, Bush AI. Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. Int J Neuropsychopharmacol. 2008;11(6):851–76.
14. Pickar DP, Murphy DL. Selective and nonselective monoamine oxidase inhibitors: behavioral disturbances during their administration to depressed patients. Arch Gen Psychiatry. 1982;39(5):535–40.
15. Riba J, Valle M, Urbano G, Yritia M, Morte A, Barbanoj MJ. Human pharmacology of ayahuasca: subjective and cardiovascular effects, monoamine metabolite excretion, and pharmacokinetics. J Pharmacol Exp Ther. 2003;306(1):73–83.
16. Riba J, McIlhenny EH, Valle M, Bouso JC, Barker SA. Metabolism and disposition of N,N-dimethyltryptamine and harmala alkaloids after oral administration of ayahuasca. Drug Test Anal. 2012;4(7-8):610–6.
17. Tondo L, Vazquez G, Baldessarini RJ. Mania associated with antidepressant treatment: comprehensive meta-analytic review. Acta Psychiatr Scand. 2010;121(6):404–14.